Effects of individual micronutrients on blood pressure in patients with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
cholecalciferol 3 endocrinologydiseasesdrugs
ergocalciferol 2 endocrinologydiseasesdrugs
paricalcitol 1 endocrinologydiseasesdrugs
type 2 diabetes mellitus 1 endocrinologydiseases
Insulin 1 endocrinologydiseasesdrugs
diabetes mellitus 2 endocrinologydiseases
hyperparathyroidism 1 endocrinologydiseases
hypocalcaemia 1 endocrinologydiseases
metformin 2 endocrinologydiseasesdrugs
secondary hyperparathyroidism 1 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Insulin 31952 years old plasma vitamin D < 50 mmol/l C.137 ± 14.1Serum 25 OHD/nmol/lDBP: −2.2 ± 8.6 Insulin = 18% Baseline: 40.2 ± 10.3 Change: 22.9 ± 16.6 DBPControlControl I.82 ± 10.5Single
cholecalciferol 16195 evaluated supplementation of ergocalciferol (vitamin D2), and six trials[19][21][22][23][24][25] evaluated cholecalciferol (vitamin D3). In three of the interventions, the patients received a single dose of vitamin D2[20] (100,000 IU)
cholecalciferol 16430 vitamin D3[19] (100,000 IU or 200,000 IU). One trial evaluated the effects of 50,000 IU/week of cholecalciferol for 12 weeks (a total dose of 600,000 IU)[22], and the other study evaluated the effects of 225,000 IU
cholecalciferol 21267 all of the evaluated studies, the supplemented vitamin D was either ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3). Although these vitamins are derived from different sources (plants, diet, or dermal synthesis),
ergocalciferol 16117 different forms of vitamin D[19][20][21][22][23][24][25]. One study[20] evaluated supplementation of ergocalciferol (vitamin D2), and six trials[19][21][22][23][24][25] evaluated cholecalciferol (vitamin D3). In three
ergocalciferol 21236 BP, especially in systolic BP. In all of the evaluated studies, the supplemented vitamin D was either ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3). Although these vitamins are derived from different sources
metformin 33627 blind/12 weeksn = 100I.8.3 ± 4.6NASBDInterventionInterventionOral antihyperglycemic = 100% ( metformin , glibenclamide, glitazones) 43% malesC.7.0 ± 5.2 I.125.7 ± 14.4Vitamin D3-fortified yogurt:
metformin 34559 weeksn = 90NAI.29.9 ± 4.7SBPIntervention (n = 30)InterventionOral antihyperglycemic = 100% ( metformin , glibenclamide, glitazones) 39% males C.29.2 ± 4.4I.131.5 ± 21.6Vitamin D3-fortified yogurt:
paricalcitol 22581 to our analysis, both of these meta-analyses[34][35] included studies that examined the effects of paricalcitol , as well as intramuscular and parenteral vitamin D, on BP. Moreover, the results of studies in which
Select Disease Character Offset Disease Term Instance
diabetes mellitus 2854 clinical trials[13][14].The relationship between individual micronutrients and BP in patients with type 2 diabetes mellitus is still uncertain. Data from individual studies[15][16][17][18][19][20][21][22][23][24][25] may not
diabetes mellitus 37978 Association; BP = blood pressure; C = control group; DBP = diastolic blood pressure; DM = diabetes mellitus ; I = intervention group; NA = not available; SBP = systolic blood pressure; y = years
hyperparathyroidism 24352 Additionally, in the presence of hypovitaminosis D, an alternative mechanism could be related to the secondary hyperparathyroidism and relative hypocalcemia that are commonly seen in these patients[38].SodiumThe effects of the reduction
hypocalcaemia 25165 patients[16]. The absence of side effects of magnesium supplementation in this trial (e.g., nausea, vomiting, hypocalcaemia , or even cardiovascular effects) was probably due to the presence of hypomagnesaemia and the use of
secondary hyperparathyroidism 24342 Additionally, in the presence of hypovitaminosis D, an alternative mechanism could be related to the secondary hyperparathyroidism and relative hypocalcemia that are commonly seen in these patients[38].SodiumThe effects of the reduction
type 2 diabetes mellitus 2847 clinical trials[13][14].The relationship between individual micronutrients and BP in patients with type 2 diabetes mellitus is still uncertain. Data from individual studies[15][16][17][18][19][20][21][22][23][24][25] may not

You must be authorized to submit a review.